Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)

Trends in Molecular Medicine

Volumn 7, Issue 9, 2001, Pages 395-400

  Sporn, Michael B ^a   Suh, Nanjoo ^a   Mangelsdorf, David J ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ANTINEOPLASTIC AGENT; LG 100641; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA MODULATOR; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRITERPENOID; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE SUSCEPTIBILITY; HUMANS; LIGANDS; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSCRIPTION FACTORS;

EID: 0034847431     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02100-1     Document Type: Review

References (75)

1. Chemoprevention of cancer
2. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
3. Tamoxifen, raloxifene, and the prevention of breast cancer
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
6. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
7. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
8. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen
9. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
10. EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro
11. 1α,25-Dihydroxy-16-ene-23-yne-26-27-hexafluorocholecaliciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat
12. Prevention of cancer in the next millennium: Report of the chemoprevention working group to the American Association for Cancer Research
13. The nuclear receptor superfamily: The second decade
14. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
15. The RXR heterodimers and orphan receptors
16. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
17. The PPARs: From orphan receptors to drug discovery
18. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
19. The war on cancer
20. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
21. Loss-of-function mutations in PPARγ associated with human colon cancer
22. PAX8-PPAR γ fusion in oncogene human thyroid carcinoma
23. The role of PPAR-γ as a tumor suppressor gene in colon carcinogenesis
24. Constitutive PPARγ signaling accelerates breast tumor development
25. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
26. The molecular pharmacology of SERMs
27. Estrogen receptors: Selective ligands, partners, and distinctive pharmacology
28. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-α and estrogen receptor-β: Correlations with biological character and distinct differences among SRC coactivator family members
29. PPARγ and treatment of insulin resistance
30. A selective peroxisome proliferator-activated receptor-γ (PPARγ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes
31. Activation of specific RXR heterodimers by an antagonist of RXR homodimers
32. Cytokines in context
33. Role of transforming growth factor-β signaling in cancer
34. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
35. A new ligand for the peroxisome proliferator-activated receptor γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis
36. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC Min/+ mice
37. Activators of the nuclear receptor PPAR-γ enhance colon polyp formation
38. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer
39. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
40. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
41. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
42. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
43. The role of PPAR-γ in macrophage differentiation and cholesterol uptake
44. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), with potent differentiating, anti-proliferative, and anti-inflammatory activity
45. PPARγ nuclear receptor as a novel therapeutic target in AML
46. Terminal differentiation of human breast cancer through PPAR-γ
47. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation on PPARγ
48. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase
49. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
50. Differentiation and reversal of malignant changes in colon cancer through PPAR-γ
51. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
52. Transcriptional control - Sinful repression
53. The coregulator exchange in transcriptional functions of nuclear receptors
54. Increasing the complexity of coactivation in nuclear receptor signaling
55. Discrete roles for peroxisome proliferator-activated receptor γ and retinoid X receptor in recruiting nuclear receptor coactivators
56. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
57. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1
58. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
59. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling
60. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
61. PPARγ agonists inhibit production of monocyte inflammatory cytokines
62. A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response
63. TGFβ signaling in growth control, cancer, and heritable disorders
64. Phosphorylation meets ubiquitination: The control of NF-κB activity
65. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ
66. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB
67. Role of the histone deacetylase complex in acute promyeolocytic leukaemia
68. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
69. Retinoids and demethylating agents - Looking for partners
70. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer
71. Atherosclerosis: The road ahead
72. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
73. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
74. The hormone resistin links obesity to diabetes
75. Tumour suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN